Evidence map›Paper›PMID 20649491›Full record

ArticleAntioxidants & redox signaling2011

Glucose-6-phosphate dehydrogenase is a regulator of vascular smooth muscle contraction.

Rakhee S Gupte, Hirotaka Ata, Dhawjbahadur Rawat, Madoka Abe, Mark S Taylor, Rikuo Ochi, Sachin A Gupte

Abstract read
In one paragraph

Article in Antioxidants & redox signaling, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.

0numbers the graph read from it
0cells of the map it votes in
24citing papers in PubMed
1.7field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

24 citing papers in PubMed, 38 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Review
  9. Glucose-6-phosphate dehydrogenase increases CaAmerican journal of physiology. Heart and circulatory physiology · 2020
    Article
  10. Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Impact of glucose-6-phosphate dehydrogenase deficiency on the pathophysiology of cardiovascular disease.American journal of physiology. Heart and circulatory physiology · 2013
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Rakhee S GupteDepartment of Biochemistry, University of South Alabama, College of Medicine, Mobile, Alabama 36688, USA.
Hirotaka Ata
Dhawjbahadur Rawat
Madoka Abe
Mark S Taylor
Rikuo Ochi
Sachin A Gupte
University of South Alabama · US

Funding

Regulation of Vascular Smooth Muscle Cell Phenotype by a Novel Isoform of Glucose-6-Phosphate DehydrogenaseR01HL132574 · NHLBI · NEW YORK MEDICAL COLLEGE · PI GUPTE, SACHIN A, MIANO, JOSEPH M · 2017 to 2020
$2.5M
Regulation of Vascular Smooth Muscle Calcium by NADPH RedoxR01HL085352 · NHLBI · UNIVERSITY OF SOUTH ALABAMA · PI GUPTE, SACHIN A · 2008 to 2012
$1.9M
Coronary Artery Regulation by Small Conduction Ca2+-activated K+ ChannelsR01HL085887 · NHLBI · UNIVERSITY OF SOUTH ALABAMA · PI TAYLOR, MARK STEPHEN · 2007 to 2011
$1.3M
NHLBI NIH HHS R01 HL085352NHLBI NIH HHS R01HL085352NHLBI NIH HHS R01 HL085887NHLBI NIH HHS R01 HL132574
6 · The paper itself

Abstract

Glucose-6-phosphate dehydrogenase (G6PD) is the rate-limiting enzyme in the pentose phosphate pathway and a major source of nicotinamide adenine dinucleotide phosphate reduced (NADPH), which regulates numerous enzymatic (including glutathione reductase and NADPH oxidase that, respectively, generates reduced glutathione and reactive oxygen species) reactions involved in various cellular actions, yet its physiological function is seldom investigated. We, however, recently showed that inhibiting G6PD causes precontracted coronary artery (CA) to relax in an endothelium-derived relaxing factor- and second messenger-independent manner. Here we assessed the role of G6PD in regulating CA contractility. Treating bovine CAs for 20 min with potassium chloride (KCl; 30 mM), amphotericin B (50 μM), or U46619 (100 nM) significantly (p < 0.05) increased both G6PD activity and glucose flux through the pentose phosphate pathway. The effect was Ca(2+) independent, and there was a corresponding increase in protein kinase C (PKC) activity. Activation of G6PD by KCl was blocked by the PKCδ inhibitor rottlerin (10 μM) or by knocking down PKCδ expression using siRNA. Phorbol 12, 13-dibutyrate (10 μM), a PKC activator, significantly increased G6PD phosphorylation and activity, whereas single (S210A, T266A) and double (S210A/T266A) mutations at sites flanking the G6PD active site significantly inhibited phosphorylation, shifted the isoelectric point, and reduced enzyme activity. Knocking down G6PD decreased NADPH and reactive oxygen species generation, and reduced KCl-evoked increases in [Ca(2+)](i) and myosin light chain phosphorylation, thereby reducing CA contractility. Similarly, aortas from G6PD-deficient mice developed less KCl/phorbol 12, 13-dibutyrate-evoked force than those from their wild-type littermates. Conversely, overexpression of G6PD augmented KCl-evoked increases in [Ca(2+)](i), thereby augmenting CA contraction. Our findings demonstrate that G6PD activity and NADPH is increased in activated CA in a PKCδ-dependent manner and that G6PD modulates Ca(2+) entry and CA contractions evoked by membrane depolarization.

Indexed as

AnimalsBlotting, WesternCalciumCell LineGlucosephosphate DehydrogenaseHumansImmunohistochemistryImmunoprecipitationMiceMice, TransgenicMuscle ContractionMuscle, Smooth, VascularPhosphorylationCalciumGlucosephosphate Dehydrogenase

Identifiers

PMID20649491
PMCPMC3029003
OpenAlexW2034385165

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.